ReviewOncology reviews2016
Urinary Bladder Cancer: Biomarkers and Target Therapy, New Era for More Attention.
Review in Oncology reviews, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- HCN2 Promotes BGN Transcription via REST to Regulate Ferroptosis and Tumor Progression in Bladder Cancer.International journal of molecular sciences · 2026Article
- Artificial intelligence-assisted diagnosis and histopathological grading of bladder cancer: current status, challenges, and future directions.Frontiers in digital health · 2026Review
- Long non-coding RNA PCAT6 regulates bladder cancer progression via the microRNA-143-3p/PDIA6 axis.Experimental and therapeutic medicine · 2021Article
- The inhibitory effect of silencing CDCA3 on migration and proliferation in bladder urothelial carcinoma.Cancer cell international · 2021Article
- Tumor heterogeneity in muscle-invasive bladder cancer.Translational andrology and urology · 2020Review
- Matrix Metalloproteinase 11 is a Potential Biomarker in Bladder Cancer Diagnosis and Prognosis.OncoTargets and therapy · 2020Article
- Downregulation of miR-200c stabilizes XIAP mRNA and contributes to invasion and lung metastasis of bladder cancer.Cell adhesion & migration · 2019Article
- Long Non-coding RNA DLEU1 Promotes Cell Proliferation, Invasion, and Confers Cisplatin Resistance in Bladder Cancer by Regulating the miR-99b/HS3ST3B1 Axis.Frontiers in genetics · 2019Article
- Urovysion FISH Could Be Effective and Useful Method to Confirm the Identity of Cultured Circulating Tumor Cells from Bladder Cancer Patients.Journal of Cancer · 2019Article
- Neural precursor cell expressed, developmentally downregulated 8 promotes tumor progression and predicts poor prognosis of patients with bladder cancer.Cancer science · 2019Article
- Overexpression of long non‑coding RNA n346372 in bladder cancer tissues is associated with a poor prognosis.Molecular medicine reports · 2018Article
- Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder.International journal of molecular sciences · 2018Article
- The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
- RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.Oncology letters · 2018Article
- Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M.Cellular and molecular life sciences : CMLS · 2018Article
- Update on the Treatment of Metastatic Urothelial Carcinoma.TheScientificWorldJournal · 2018Review
- Expression of MDM2 mRNA, MDM2, P53 and P16 Proteins in Urothelial Lesions in the View of the WHO 4Open access Macedonian journal of medical sciences · 2017Article
- MiR-26a inhibits cell proliferation and induces apoptosis in human bladder cancer through regulating EZH2 bioactivity.International journal of clinical and experimental pathology · 2017Article
- Identification of Biomarkers Correlated with the TNM Staging and Overall Survival of Patients with Bladder Cancer.Frontiers in physiology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Currently, bladder cancer (BCa) evaluation depends mainly on traditional clinicopathological parameters encompassing tumor stage and grade, which will not reflect the behavior of the disease. Diverse molecular alterations are responsible for the heterogeneous course. The differences in molecular pathogenesis between non-invasive BCa and invasive BCa have been recognized. Molecular biomarkers are promising to predict progression and survival. The management of advanced BCa remains somewhat primitive in comparison with other more common malignancies. This topic will discuss the molecular pathways, biomarkers and potential targets that may improve the outcome in BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.